

ZIOPHARM Oncology, Inc. Investor Relations Department One First Ave., Parris Building, # 34 Navy Yard Plaza Boston, MA 02199 United States

Visit IR website ☐ Sign-up for Email alerts ☐

5.87
4:00 PM ET Jul 24, 2017
00 (0.000%)
N/A - N/A
4.55 - 7.88
N/A


Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

# **Company Profile**

ZIOPHARM Oncology, Inc. is a biopharmaceutical company that is seeking to develop and commercialize a diverse portfolio of treatments for people with cancer and graft-versus-host-disease. Our focus is on the development of cell and viral-therapies using a suite of technologies that employing novel gene expression, control and cell technologies to deliver safe, effective and scalable therapies.

... (more)

#### **Stock Performance**



### Press Releases [View all]

Jul 24, 2017

ZIOPHARM Oncology to Host Second-Quarter 2017 Financial Results and Corporate Update Conference Call on July 31, 2017 at 4:30 p.m. ET

Jun 28, 2017

ZIOPHARM Oncology Announces Initiation of Stereotactic Treatment Cohort in Phase 1 Study of Ad-RTS-hIL-12 + Veledimex in Recurrent Glioblastoma

Jun 5, 2017

ZIOPHARM Oncology Announces Positive Updated Results of Ad-RTS-hIL-12 + Veledimex in Recurrent Glioblastoma at the 2017 ASCO Annual Meeting

Jun 2, 2017

ZIOPHARM to Present at the Jefferies 2017 Global Healthcare Conference

May 17, 2017

ZIOPHARM Oncology Announces Results of Ad-RTS-hIL-12 + Veledimex in Recurrent Glioblastoma to be Presented at the 2017 ASCO Annual Meeting

### Upcoming Events [View all]

Jul 31, 2017 4:30 PM ET
Ziopharm Second Quarter 2017 Financial
Results Conference Call

# Financials [View all]

Feb 16, 2017 Annual Report (10-K)

Apr 28, 2017
Proxy Statement (DEF 14A)

May 1, 2017
Quarterly Report (10-Q)

Nov 9, 2016

Quarterly Report (10-Q)

Aug 9, 2016

Quarterly Report (10-Q)